TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02081534

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid, double dummy technique
Study: NCT01014351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus, 5 mg by mouth (PO) once a day, continuous dosing every 21-day cycle
Study: NCT02241759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02835183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iDECIDE
Description: The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iDECIDE
Description: The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.
Study: NCT03093571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular stimulation
Description: Auricular stimulation with indwelling fixed needles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Progressive muscle relaxation
Study: NCT02432755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based MTOT
Description: The home-based MTOT group will receive 30 minutes of MT followed by 30 minutes of TOT per session. The intervention will take place in the participant's home environment. During the mirror practices, the patient will seat close to a table which the mirror box will be placed at the mid-sagittal plane. During MT, the participant will be encouraged to actively move their paretic arm and hand concurrently with the mirror reflection of the movement of the nonparetic arm and hand as possible as they can. If necessary, the therapist will assist the participant in moving the paretic hand to synchronize the movement with the nonparetic hand.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hospital-based therapy
Description: The control group will receive a dose-matched, individualized occupational therapy at a hospital. The participants will receive customary rehabilitation programs as usual performed at hospitals for 1 hour per session. The treatment protocol will include: (a) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques, (b) fine motor or dexterity training, (c) arm exercises or gross motor training, (d) muscle strengthening of the affected upper limb, and (e) activities of daily living training or functional task practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hospital-based MTOT
Description: The hospital-based MTOT group will also receive 30 minutes of MT followed by 30 minutes of TOT per session at a hospital. The intervention will take place in the occupational therapy clinic. The treatment modalities in the hospital will be selected and provided for this group. Most of the treatment principles and components are the same as aforementioned in the home-based MTOT. However, the major differences between home-based and hospital-based MTOT are the treatment contexts, environments and functional modalities used.
Study: NCT03074552

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LactoLevure
Description: The probiotic preparation will consist a combination of four probiotics: Lactobacillus acidophilus LA-5 1.75 × 109 CFU, Lactobacillus Plantarum 0.5 × 109 CFU, Bifidobacterium lactis BB-12 1.75 × 109 CFU και Saccharomyces boulardii 1.5 × 109 CFU per capsule (LactoLevure, UniPharma, Athens, Greece).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of identical capsules of powdered glucose polymer
Study: NCT01705509

Intervention type: DRUG
Group type: OTHER
Intervention: Ranolazine
Description: The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
Study: NCT03611855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI Rehabilitation
Description: Patients use electroencephalography (EEG) signals to control a motorized glove worn on their affected hand. The glove moves the patient's hand according to the type of signal detected (Rest vs Motor Imagery).
Study: NCT04877951

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LSVT BIG
Description: LSVT BIG is a 4-week program that focuses on movement recalibration for people with a diagnosis of Parkinson's disease.
Study: NCT01640392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyLife MyStyle group-level intervention
Description: Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
Study: NCT02383212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study: NCT02177149

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients in the standard of care arm will have their DBS programmed per standard of care which is testing multiple settings and looking for symptom relief through a trial and error process.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS using Clinical Support System.
Description: The DBS RN (Registered Nurse) will use ImageVis3D Mobile app on the iPad to program the DBS system, this software does not interact with imaging systems. The study team uses identified images provided by the Froedtert PACS system, de identifies them, adds a study code. The images are loaded into the software system and used to identify the leads locations. The Patients will be assessed for 6 months starting with the initial DBS programming session. Importantly, the investigators do not anticipate that the clinical decision support tool will provide the final DBS settings, nor do the investigators anticipate that the approach will obviate the need for motor exams. The clinical decision support system will help nurses choose good initial settings and then explore around those initial settings.
Study: NCT03681262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency spinal cord stimulation
Description: We will use Senza® (Nevro Corp., Palo Alto, CA) trial and implant systems to deliver high frequency spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. High frequency waveform will be delivered with following parameters: frequency of 10,000 hertz, pulse width of 20 microseconds, and amplitude of 0-15 milliamperes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst spinal cord stimulation
Description: We will use BusrtDRTM (Abbott Saint Jude Medical, St. Paul, MN) trial and implant systems to deliver burst spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. The parameters of the stimulation are as below: each burst includes 5 pulses of electrical stimulation at intra-burst frequency of 500 hertz without time for discharge in between pulses. These bursts will be repeated at inter-burst frequency of 40-60 hertz. The amplitude will range between 0 and 15 milliamperes.
Study: NCT03611855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Range of Motion Therapy
Description: Patients repeatedly move or stretch the joints and muscles of their affected limb, either by actively moving the limb or assisting the limb with no active motion.
Study: NCT04893642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture rectopexy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection rectopexy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delorme's operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Altemeier's operation
Study: NCT02569788

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (CIRT)
Description: Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
Study: NCT00701883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 capsules, once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 capsules, once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 capsules, once a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules, once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025
Description: 2 capsules, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025
Description: 2 capsule, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 2 capsules, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 2 capsules, once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 2 capsules, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025
Description: 2 capsules, once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025
Description: 2 capsules, once daily for 8 weeks
Study: NCT02796313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH Groceries + Weekly Sessions
Description: Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Groceries + Brochure
Description: Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $35 grocery order for 8 weeks.
Study: NCT04212962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional care model (TCM)
Description: Patient education about post-discharge self-care and medications, arrangement of needed social services, coordination of information from medical providers interacting with patient

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: usual hospital discharge and post-discharge care
Study: NCT02563067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 450 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT04014868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high-flow
Description: See arm description.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham nasal high-flow
Description: See arm description.
Study: NCT03536416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Asthma in School
Description: The intervention will include three arms. During the theatre workshop, the children will watch a theatre performance, and engage in a discussion at the end of the play, about what they have watched. The self-management workshops will cover a range of topics identified as barriers to self-management in our earlier study, and will be delivered to children with asthma only. The control group will receive usual care during the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Asthma in School
Description: The intervention will include three arms. During the theatre workshop, the children will watch a theatre performance, and engage in a discussion at the end of the play, about what they have watched. The self-management workshops will cover a range of topics identified as barriers to self-management in our earlier study, and will be delivered to children with asthma only. The control group will receive usual care during the intervention.
Study: NCT00000414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis Self-Management Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Program
Study: NCT01093027

Intervention type: OTHER
Group type: OTHER
Intervention: 15 - 30
Description: The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.

Intervention type: OTHER
Group type: OTHER
Intervention: 30 - 15
Description: The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
Study: NCT01994096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Study: NCT03310853

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Dosing regimen of one capsule daily for a maximum of 18 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing regimen of one capsule daily for a maximum of 18 weeks
Study: NCT01374230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Primary total knee arthroplasty surgery for the treatment of osteoarthritis.
Study: NCT03428035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Package Insert
Description: Modified package insert of Ibuprofen given postprocedural as pain medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Package Insert
Description: Modified package insert of Ibuprofen given postprocedural as pain medication
Study: NCT02644603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery
Description: Before operation:~Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.~In operation:~Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.~After operation:~Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization.
Study: NCT04286061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assisted soft tissue mobilization
Description: It will be done for 60 seconds, making a total of 30 strokes with the tool in the longitudinal direction to the muscle fibers. The physiotherapist will previously apply some massage cream to the area to be treated (adductor musculature) so that the tool slides at a 45º angle. Landslides will be made from the femoral condyle to the groin, and vice versa, exerting a pressure with the instrument of 3 over 10 on the analog visual scale that the subject feels
Study: NCT04155138

Intervention type: DEVICE
Group type: OTHER
Intervention: Naida Hearing Aid
Description: hearing aid

Intervention type: DEVICE
Group type: OTHER
Intervention: Naida Hearing Aid
Description: hearing aid

Intervention type: DEVICE
Group type: OTHER
Intervention: Naida Contralateral Routing of Sound Device
Description: This is a device that routes sound to the non-cochlear implanted ear.

Intervention type: DEVICE
Group type: OTHER
Intervention: Naida Contralateral Routing of Sound Device
Description: This is a device that routes sound to the non-cochlear implanted ear.
Study: NCT02526706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VisionBlue
Description: VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
Study: NCT04956380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered Triage
Description: Self-assessment including a self-administered patient joint count and a self-administered Early Inflammatory Arthritis Detection Tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered Triage
Description: Self-assessment including a self-administered patient joint count and a self-administered Early Inflammatory Arthritis Detection Tool
Study: NCT05538715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split-thickness group
Description: Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full-thickness group
Description: Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.
Study: NCT03507387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .
Study: NCT04956380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered Triage
Description: Self-assessment including a self-administered patient joint count and a self-administered Early Inflammatory Arthritis Detection Tool
Study: NCT03067883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir, Paritaprevir and Ritonavir
Description: A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~* These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~* Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~* Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session ).
Study: NCT03507387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .
Study: NCT02447588

Intervention type: OTHER
Group type: OTHER
Intervention: IAD at 36 hours
Description: Intrauterine insemination with sperm donor at 36 hours post-hCG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IAD at 24 hours
Description: Intrauterine insemination with sperm donor at 24 hours post-hCG